Cited 33 time in
Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, E.-J. | - |
| dc.contributor.author | Kang, G.-J. | - |
| dc.contributor.author | Kang, J.-I. | - |
| dc.contributor.author | Boo, H.-J. | - |
| dc.contributor.author | Hyun, J.W. | - |
| dc.contributor.author | Koh, Y.S. | - |
| dc.contributor.author | Chang, W.-Y. | - |
| dc.contributor.author | Kim, Y.R. | - |
| dc.contributor.author | Kwon, J.-M. | - |
| dc.contributor.author | Maeng, Y.H. | - |
| dc.contributor.author | Yoo, E.-S. | - |
| dc.contributor.author | Lee, C.H. | - |
| dc.contributor.author | Kang, H.-K. | - |
| dc.date.accessioned | 2023-04-28T10:40:40Z | - |
| dc.date.available | 2023-04-28T10:40:40Z | - |
| dc.date.issued | 2018-04-13 | - |
| dc.identifier.issn | 1949-2553 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/9921 | - |
| dc.description.abstract | Here, we investigated whether over-activation of AKT pathway is important in the resistance to 5-fluorouracil (5-FU) in SNU-C5/5-FU cells, 5-FU-resistant human colon cancer cells. When compared to wild type SNU-C5 cells (WT), SNU-C5/5-FU cells showed over-activation of PI3K/AKT pathway, like increased phosphorylation of AKT, mTOR, and GSK-3β, nuclear localization of β-catenin, and decreased E-cadherin. Moreover, E-cadherin level was down-regulated in recurrent colon cancer tissues compared to primary colon cancer tissues. Gene silencing of AKT1 or treatment of LY294002 (PI3 kinase inhibitor) increased E-cadherin, whereas decreased phospho- GSK-3β. LY294002 also reduced protein level of β-catenin with no influence on mRNA level. PTEN level was higher in SNU-C5/WT than SNU-C5/5-FU cells, whereas the loss of PETN in SNU-C5/WT cells induced characteristics of SNU-C5/5-FU cells. In SNU-C5/5-FU cells, NF-κB signaling was activated, along with the overexpression of COX-2 and stabilization of survivin. However, increased COX-2 contributed to the stabilization of survivin, which directly interacts with cytoplasmic procaspase-3, while the inhibition of AKT reduced this cascade. We finally confirmed that combination treatment with 5-FU and LY294002 or Vioxx could induce apoptosis in SNU-C5/5- FU cells. These data suggest that inhibition of AKT activation may overcome 5-FUresistance in SNU-C5/5-FU cells. These findings provide evidence that over-activation of AKT is crucial for the acquisition of resistance to anticancer drugs and AKT pathway could be a therapeutic target for cancer treatment. © Kim et al. | - |
| dc.format.extent | 18 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Impact Journals LLC | - |
| dc.title | Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.18632/oncotarget.24952 | - |
| dc.identifier.scopusid | 2-s2.0-85045343678 | - |
| dc.identifier.bibliographicCitation | Oncotarget, v.9, no.28, pp 19911 - 19928 | - |
| dc.citation.title | Oncotarget | - |
| dc.citation.volume | 9 | - |
| dc.citation.number | 28 | - |
| dc.citation.startPage | 19911 | - |
| dc.citation.endPage | 19928 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.subject.keywordAuthor | 5-Fluorouracil resistance | - |
| dc.subject.keywordAuthor | COX-2 | - |
| dc.subject.keywordAuthor | E-cadherin | - |
| dc.subject.keywordAuthor | Over-activation of AKT | - |
| dc.subject.keywordAuthor | SNU-C5/5-FU | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
